Log in to search using one of your social media accounts:


Mixed Results for Brachytherapy in Breast Cancer (CME/CE)

(MedPage Today) -- Older breast cancer patients had an increased rate of subsequent mastectomy if they received brachytherapy instead of external-beam radiation therapy after lumpectomy but fared better than patients who received no radiation, investigators reported.
Source: MedPage Today Surgery - Category: Surgery Source Type: news

Related Links:

Grandview Medical Center has named Jennifer De Los Santos as the medical director of the new Grandview Cancer Center.   Dr. De Los Santos has been nationally recognized for her work in radiation oncology, specifically her research in breast cancer treatment. Prior to joining Grandview, she was an associate scientist and professor at the University of Alabama at Birmingham in the department of radiation oncolog y. She also served as medical director of The Kirklin Clinic.  Dr. De Los Santos has…
Source: bizjournals.com Health Care:Physician Practices headlines - Category: American Health Authors: Source Type: news
Conditions:   HER2-positive Breast Cancer;   Breast Cancer;   Breast Cancer Stage;   Recurrent Breast Cancer;   Metastatic Breast Cancer;   HER2 Positive Breast Carcinoma Interventions:   Drug: Palbociclib;   Drug: T-DM1 Sponsors:   University of Arizona;   Pfizer Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Guideposts to powerful treatments may be buried in the nation ’ s medical records. But there is no easy way to gather those records or to get them into a usable format.
Source: NYT Health - Category: Consumer Health News Authors: Tags: Genetics and Heredity Tumors Cancer Breast Cancer Flatiron Health Inc National Cancer Institute Source Type: news
Recent survival results lead some to question the optimal sequence for trastuzumab emtansine in metastatic breast cancer.Chinese Clinical Oncology
Source: Medscape Today Headlines - Category: Consumer Health News Tags: Hematology-Oncology Journal Article Source Type: news
(Mayo Clinic) In a recent study published in the Journal of Clinical Investigation, Mayo Clinic researchers identified that an FDA drug approved for myelodysplastic syndrome may be useful to treat triple-negative breast cancer, which is one of the most aggressive and lethal types of breast cancer.
Source: EurekAlert! - Cancer - Category: Cancer & Oncology Source Type: news
In conclusion, these results overall suggest that primary tumors showing sensitivity to continuous pazopanib treatment may predict response to this drug when given at high doses intermittently in the context of advanced metastatic disease, that are otherwise resistant to the conventional protocol.
Source: Angiogenesis - Category: Molecular Biology Source Type: research
The Breast Journal, EarlyView.
Source: The Breast Journal - Category: Cancer & Oncology Authors: Source Type: research
We report on two sisters originally suspected of having CMMRD syndrome due to their history of colonic polyps and NF1 associated skin findings, both were subsequently found to have biallelicMSH6 mutations. After years of CMMRD syndrome follow-up, the proband was diagnosed with breast cancer at age 29, while her sister was diagnosed with a glioblastoma at age 27. Immunohistochemistry analysis on the breast tumor tissue revealed weak MSH6 protein staining. Exome sequencing revealed a hypermutated breast tumor and an ultra-hypermutated brain tumor. Multi-gene panel testing was also performed and revealed no additional mutatio...
Source: Familial Cancer - Category: Cancer & Oncology Source Type: research
The Breast Journal, EarlyView.
Source: The Breast Journal - Category: Cancer & Oncology Authors: Source Type: research
The Breast Journal, EarlyView.
Source: The Breast Journal - Category: Cancer & Oncology Authors: Source Type: research
More News: Brachytherapy | Breast Cancer | Breast Lumpectomy | Cancer | Cancer & Oncology | External Beam Therapy | Lumpectomy | Mastectomy | Radiation Therapy | Surgery